Zoetis ZTS
NYSE ZTS
$75.69 -0.99 (-1.29%)
At close: Aug 20, 2026 · 10:53 AM UTC

Zoetis (ZTS) Liabilities and Shareholders Equity (2012 - 2026)

Zoetis (ZTS) posted quarterly Liabilities and Shareholders Equity of $15.2 billion for Q1 2026, up 7.49% year-over-year from $14.1 billion in Q1 2025, and down 2.17% quarter-over-quarter from $15.5 billion in Q4 2025.

Zoetis (ZTS) Liabilities and Shareholders Equity (2012 - 2026) Analysis & Trends

Zoetis (ZTS) has reported Liabilities and Shareholders Equity for 15 consecutive years, with $15.2 billion the latest figure, recorded in Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity rose 7.49% year-over-year to $15.2 billion; the TTM figure through Mar 2026 stood at $60.3 billion (up 6.09% YoY), while the FY2025 annual figure was $15.5 billion, up 9.08% from the prior year.
  • Liabilities and Shareholders Equity retreated to $15.2 billion in Q1 2026 per ZTS's latest filing, from $15.5 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $15.5 billion in Q4 2025 and bottomed at $13.7 billion in Q3 2022.
  • Historically, Liabilities and Shareholders Equity has averaged $14.3 billion across 5 years, with a median of $14.2 billion in 2024.
  • Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity decreased 4.28% — and 2025, when it rose 9.08%.
  • Zoetis' Liabilities and Shareholders Equity stood at $14.9 billion in 2022, then retreated by 4.28% to $14.3 billion in 2023, then slipped by 0.6% to $14.2 billion in 2024, then gained by 9.08% to $15.5 billion in 2025, then fell by 2.17% to $15.2 billion in 2026.
  • Business Quant data shows ZTS's Liabilities and Shareholders Equity at $15.2 billion in Q1 2026, $15.5 billion in Q4 2025, and $15.2 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 43.76 Bn 42.79 Bn - 43.71 Bn
2 Teva Pharmaceutical Industries 43.38 Bn 39.73 Bn 2.15 Bn 39.86 Bn
3 Zoetis 31.61 Bn 29.93 Bn 1.05 Bn 15.08 Bn
4 Takeda Pharmaceutical 28.64 Bn 22.84 Bn 5.10 Bn 98.27 Bn
5 United Therapeutics 22.20 Bn 19.54 Bn 683.80 Mn 7.22 Bn
6 Viatris 18.82 Bn 17.93 Bn 1.46 Bn 35.04 Bn
7 Neurocrine Biosciences 15.67 Bn 15.28 Bn 935.80 Mn 5.36 Bn
8 Elanco Animal Health 12.11 Bn 11.58 Bn 798.00 Mn 13.56 Bn
9 Dr Reddys Laboratories 10.10 Bn 9.94 Bn - 6.18 Bn
10 Alkermes 8.21 Bn 7.55 Bn 397.90 Mn 4.39 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 15.08 Bn
Mar 31, 2026 15.15 Bn
Dec 31, 2025 15.49 Bn
Sep 30, 2025 15.16 Bn
Jun 30, 2025 14.48 Bn
Mar 31, 2025 14.10 Bn
Dec 31, 2024 14.20 Bn
Sep 30, 2024 14.36 Bn
Jun 30, 2024 14.17 Bn
Mar 31, 2024 14.35 Bn
Dec 31, 2023 14.29 Bn
Sep 30, 2023 14.11 Bn
Jun 30, 2023 13.75 Bn
Mar 31, 2023 13.75 Bn
Dec 31, 2022 14.93 Bn
Sep 30, 2022 13.67 Bn
Jun 30, 2022 13.77 Bn
Mar 31, 2022 13.86 Bn
Dec 31, 2021 13.90 Bn
Sep 30, 2021 13.71 Bn